The Application Notebook
The analysis of polar compounds in support of clinical and preclinical pharmacokinetic studies requires an analytical methodology capable of achieving ultra-low detection and quantification limits. The high sensitivity afforded by coupling HPLC with tandem mass spectrometry (MS–MS) has made it the technique of choice in this environment, but it is subject to the following limitations when reversed-phase liquid chromatography (RPLC) is used
Carl Sanchez, Monika M. Kansal, Art Dixon, Philip J. Koerner and Terrell Mathews, Phenomenex Inc., Torrance, California, USA.
The analysis of polar compounds in support of clinical and preclinical pharmacokinetic studies requires an analytical methodology capable of achieving ultra-low detection and quantification limits. The high sensitivity afforded by coupling HPLC with tandem mass spectrometry (MS–MS) has made it the technique of choice in this environment, but it is subject to the following limitations when reversed-phase liquid chromatography (RPLC) is used:
1. Polar compound elution in a highly aqueous mobile phase: Gas phase ion generation is facilitated with more volatile solvents;1 therefore, the high water content used for RPLC retention of polar compounds decreases desolvation efficiency. In addition the highly aqueous mobile phase required for retention of polar compounds increases solvent surface tension, which decreases ESI spray stability.2
2. Polar compound elution in the primary ion suppression region: Poorly retained compounds in RPLC increase the likelihood of analyte compounds eluting with the many endogenous compounds present in bioanalytical samples.These endogenous compounds compete for charge in the source and can suppress analyte ionization, reducing sensitivity and degrading LOD and LOQ. It is critical that a robust bioanalytical method separate analytes from the ion suppression region.3
Luna HILIC columns allow for improved sensitivity in the analysis of complex bioanalytical samples by creating more favorable conditions for polar compound retention and ionization.
On the Luna HILIC column, atenolol elutes in a high organic volatile mobile phase, which facilitates analyte desolvation and results in enhanced LC–MS–MS sensitivity. Polar metabolites are weakly retained under RPLC conditions and elute near the solvent front, often in the "primary ion suppression region". Under HILIC chromatographic conditions, where polar analytes are retained using high organic mobile phase, Luna HILIC strongly retains polar compounds that are otherwise weakly retained in RPLC.
The Luna HILIC column retains and elutes hydrophilic/polar compounds in highly organic mobile phase conditions, which improve analyte desolvation efficiency and ESI spray stability. The combination of these two improvements in the MS interface will often provide improved polar analyte detection and quantitation.
Figure 1
In HILIC mode, the analyte elution in the primary ion suppression region is avoided as a result of the mode's increased retention of hydrophilic compounds. This increased retention for polar compounds regularly results in less interference from endogenous sample compounds, improved sensitivity and accuracy, and reduced LOD and LOQ. The Luna HILIC column meets the requirements of a robust bioanalytical method by eluting analytes outside the primary ion suppression region.
Figure 2
It has been shown here that Luna HILIC columns can improve LC–MS–MS sensitivity of polar compounds in biological matrices in support of clinical and preclinical pharmacokinetic studies where ultra-low detection and quantification limits are highly desirable.
1. N.B. Cech and C.G. Enke, Mass Spectrom. Rev., 20, 362–387 (2001).
2. P.J. Kerbarle, Mass. Spectrom., 35, 804–817 (2000).
3. B.K. Matuszewski, M.L. Constanzer and C.M. Chavez-Eng, Anal. Chem., 75, 3019–3030 (2003).
Luna and Gemini are registered trademarks of Phenomenex Inc.
Phenomenex Inc.
411 Madrid Avenue, Torrance, California 90501, USA
tel. +1 310 212 0555 fax +1 310 328 7768
E-mail: info@phenomenex.com
Website: www.phenomenex.com
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
6PPD-Quinone Reference Materials
November 19th 2024Ensure environmental and consumer health with our standards for 6PPD-quinone testing. 6PPD-quinone has been detected in the environment and has shown toxicity to aquatic life. Chiron, by Zeptometrix® offers reference standards suitable for Draft EPA Method 1634.
Current and Future Advancements in PFAS Research
November 19th 2024This white paper explores the health risks, environmental impacts, and detection technologies associated with PFAS, along with the latest advancements in PFAS research. It also provides an overview of the regulatory landscape and emphasizes the crucial role of companies like ZeptoMetrix® in supplying PFAS reference materials, which are essential for ensuring the accuracy of testing. Lastly, the paper outlines key areas for future PFAS research.
Microplastics Reference Materials
November 19th 2024The World’s First Microplastics Reference Materials. Our scientists have focused on these emerging global threats, and are excited to share Chiron MicroPrefs®, the first commercial microplastic reference material. The MicroPref® portfolio is designed to detect the six most abundant plastics in the environment and is available in a novel, easy-to-use tablet formulation. Be among the first labs to join in the fight against microplastic pollution by exploring the NEW line of Chiron MicroPrefs® microplastic standards.